Sustained-release drug delivery system for Alzheimer's disease

A technology of senile dementia and drug delivery system, which can be applied to nervous system diseases, drug combinations, pharmaceutical formulations, etc., and can solve problems such as uneducated regulation and control

Inactive Publication Date: 2021-05-04
江苏集萃新型药物制剂技术研究所有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These patents do not teach regulation and control of ingredients for complete release of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release drug delivery system for Alzheimer's disease
  • Sustained-release drug delivery system for Alzheimer's disease
  • Sustained-release drug delivery system for Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0033] Formulation 10 was manufactured by standard manufacturing methods. For example, in one method of manufacture, a drug and other ingredients comprising a drug formulation are uniformly mixed and compressed into a solid formulation. The compressed formulation has dimensions corresponding to the internal dimensions of the area occupied by the drug formulation in formulation 10 . The formulation also corresponds to the size of the propellant it is in contact with. In this manufacturing method, the drug and other ingredients containing the ingredients are mixed with a solvent and mixed into a solid or semi-solid form by conventional methods such as ball milling, calendering, stirring or rolling, and then pressed into a predetermined shape. In the next step, the propellant composition is brought into contact with the pharmaceutical composition. The pharmaceutical composition, propellant composition can be compressed by using a conventional bilayer tablet press. The pharmace...

Embodiment 1

[0038] An osmotic formulation for controlled and sustained release memantine prepared as follows: 200 g of memantine, 300 g of hydroxypropylcellulose with a molecular weight of 60,000, 295 g of carboxymethylcellulose with a molecular weight of 90,000 Sodium and 100 g of polyvinylpyrrolidone with a molecular weight of 40,000 were mixed and sieved through a 40 mesh. The sieved composition was then placed in a Glatt fluid bed granulator, mixed and heated slightly to 35°C to produce a homogeneous blended powder. Next, a binder consisting of 100 g of polyvinylpyrrolidone (40000 molecular weight in 400 ml of purified water) was sprayed onto the fluidized powder.

[0039] After the spray cycle begins, the process is monitored to ensure uniformity. The granules were dried in situ and sieved through a 16 mesh screen. Next, 5 g of magnesium stearate was sieved through an 80 mesh screen, added to the granules in the blender, and blended into a homogeneous composition. The composition ...

Embodiment 2

[0044] The preparation for administering a drug to a patient according to claim 1, wherein the preparation comprises a certain amount of an oral drug having a molecular weight of 10,000 to 300,000, hydroxypropylcellulose, polyvinylpyrrolidone and carboxymethylcellulose.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a sustained-release drug delivery system for Alzheimer's disease, and belongs to the technical field of pharmaceutical preparations. The sustained-release drug delivery system comprises a first composition containing a drug and carboxymethyl cellulose, and a second composition containing carboxymethyl cellulose, wherein the molecular weight of the carboxymethyl cellulose in the second composition is higher than that of the carboxymethyl cellulose in the first composition. The first composition and the second composition cooperate to release the maximum dose of the drug, and the residual drug in the preparation is the least. Another purpose of the present invention is to provide a pharmaceutical dosage form for in vivo release treatment of Alzheimer's disease, wherein the pharmaceutical dosage form can be released from the device by using two different polymers so as to achieve good treatment effect.

Description

technical field [0001] The invention relates to a sustained and controlled release drug delivery system for senile dementia, belonging to the technical field of pharmaceutical preparations. Background technique [0002] Controlled-release dosage forms are becoming more and more important to achieve good therapeutic effects when delivering drugs to animals. Controlled drug release from dosage forms is demonstrated by controlling the duration and release profile of drug release. Controlled-release dosage forms offer many therapeutic advantages over conventional dosage forms. For example, a major and important advantage is the reduction of fluctuations in blood drug concentrations. The pharmacological basis for reducing the fluctuation of blood drug concentration comes from the following three principles. First, each drug must achieve a drug blood level at which it is effective if the desired therapeutic effect is to be obtained from the drug. Second, most drugs have an upp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/12A61K9/20A61K47/38A61K47/32A61K31/445A61K31/4748A61K31/13A61K31/27A61K31/55A61K31/4422A61K31/48A61P25/28
CPCA61K9/0004A61K9/12A61K9/2027A61K9/2054A61K31/13A61K31/27A61K31/4422A61K31/445A61K31/4748A61K31/48A61K31/55A61K47/32A61K47/38A61P25/28
Inventor 全丹毅
Owner 江苏集萃新型药物制剂技术研究所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap